
Topics
Meeting category
Date(s)
2 Dec 2022 - 3 Dec 2022
Location
Amsterdam,
Netherlands
Meeting type
Hybrid Meeting
CME Credits
8

Meeting Organizers

Co-Convener
Sponsor logos

International Viral Hepatitis Elimination Meeting (IVHEM) 2022
Related Enduring Materials
Enduring Materials
Day 1 - Friday, December 2
Session 1: Hepatitis Elimination - Where Do We Stand? -
Progress Towards Hepatitis Elimination: WHO Perspective
The Lancet Gastroenterology & Hepatology Commission
The Global Review: Update on 25 National Profiles
John Ward, MD
Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States
The Colombian National Program on Hepatitis Elimination
The Nigerian National Program on Hepatitis Elimination
Ganiyu Jamiyu, MBBS, MPH-Epid., FMCPH, WACP
Viral Hepatitis Control Desk, Federal Ministry of Health, Nigeria
The Philippine National Program on Hepatitis Elimination
Diana Alcantara-Payawal, MD, DTMH, FPCP, FPSG, FPSDE, LIM-SEA(HMS)
Fatima University Medical Center, Philippines
The Bangladeshi National Program on Hepatitis Elimination
Mamun Al Mahtab Shwapnil, MBBS, MSc, MD, FACG, FICP, FRCP
Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh
Session 2: Capacity-Building Session -
The UN Group of Friends to Eliminate Hepatitis
Nida Ali, MBBS
Task Force for Global Health - Coalition for Global Hepatitis Elimination, Georgia, United States
New Global Initiatives
Abdulaziz Mohammed, MBBS, MHPM, MPH-FE, FWACP
Africa Centres for Disease Control and Prevention, Ethiopia
Global Fund
The Hepatitis Fund
Hepatitis Zero Program in Brazil and Africa
CDA Foundation - Using the Netflix Model to Eliminate HCV
Panel Discussion
Industry-supported Symposium*
Day 2 - Saturday, December 3
Session 3: Hepatitis C Elimination - How Do We Get to the 2030 Targets -
Diagnosis: Impact of Stigma on Diagnosis of Hepatitis C
Treatment: Do we need new DAAs, new (long-acting) formulations, and simplification?
#1 A cluster randomized controlled study of the secondary distribution of HCV self-tests in households in the general population to support micro-elimination in Karachi, Pakistan
Aliya Hasnain, MBBS
Aga Khan University Hospital, Pakistan
#2 Progress towards WHO HCV elimination incidence targets among people with HIV: findings from the International Collaboration on Hepatitis C Elimination in HIV Cohorts
Daniëla van Santen, PhD
Burnet Institute, Australia
#3 Hepatitis C seroconversion among individuals with repeated testing in the country of Georgia, 2017-2021
Davit Baliashvili, PhD
The Task Force For Global Health, Georgia
#4 Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies
Robert Flisiak, MD, PhD
Medical University of Bialystok, Poland
#5 Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia
Muhammad Radzi Abu Hassan
Clinical Research Centre, Hospital Sultanah Bahiyah, Malaysia
Session 4: Hepatitis B Cure - Overcoming the Challenges -
Treatment Challenges of HBV HBeAg Negative Patients
Marcelo Silva, MD
Latin American Association for the Study of the Liver, Austral University Hospital, Argentina
Patient Perspective on HBV Treatment & Cure
#6 Results of a novel Hepatitis Delta Virus reflex diagnosis patient pathway in Valencia, Spain
Neus Gomez-Muñoz
Hospital General Universitario de Valencia, Spain
#7 Documenting Hepatitis B Discrimination Globally and Its Impact
Catherine Freeland, MPH
Hepatitis B Foundation, United States
Panel Discussion: What Do We Need to Screen and Monitor for Responses to Functional Cure for HBV -
Status of the HBV Functional Cure and the Role of Testing
Geoffrey Dusheiko, MBBS, FCP(SA), FRCS
King's College Hospital / University College London Medical School, United Kingdom
Industry - Perspectives on Overcoming the Roadblocks**
Panel Discussion
Session 5: Abstract Driven Presentations -
#8 Accelerating triple elimination of mother-to-child transmission of hepatitis B, HIV, and syphilis: Preliminary results from a demonstration project in Nghe An, Vietnam
Bao Vu, MD, MA
PATH, Vietnam
#9 Status of Key Interventions and Essential Policies for HBV and HCV elimination in sub-Saharan Africa: A Summary of National Hepatitis Elimination Profiles from Six High-Burden Countries
Lindsey Hiebert, MPH, BS
Coalition for Global Hepatitis Elimination, Task Force for Global Health, United States
#10 Changes in hepatitis B and hepatitis C mortality rates in Central Asia from 2015 to 2019 and reduction in mortality needed to reach 2030 WHO viral hepatitis mortality elimination targets
Quincy Sanderlin, MS, MPH
Centers For Disease Control And Prevention, United States
#11 Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for marginalised populations at a mobile testing unit in Madrid, Spain
Jeffrey V. Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain / CUNY Graduate School of Public Health and Health Policy, United States
#12 Changes in the prevalence of hepatitis B and C viral infections among adults in Sindh province, Pakistan: findings from two sero-surveys in 2007 and 2019
Tesfa Sewunet Alamneh
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
Discussion / Q&A
Simplification and Linkage to Care For Adolescence and Children
Closing Remarks
* The full program of the "Industry-supported Symposium" session can be visited in the "Symposium" Tab
** The full program of the "Industry - Perspectives on Overcoming the Roadblocks" session can be visited in the "Symposium" Tab
Symposium
Overview
Registration
Abstracts
Committees
Partners
Support
Photo Gallery
Previous Editions